Neil Blumberg: Clinical Harm Associated With Infusion of ABO Incompatible Antibody and Antigen
Neil Blumberg, Transfusion Medicine Specialist and Platelet Researcher (Former Professor and Director, URMC), shared on LinkedIn:
“Some ideas become dogma without any strong data to support them. Examples include the equivalent safety of universal donor group O red cells and group AB plasma to ABO identical transfusions. Data have now accumulated to show that these assumptions are largely incorrect.
Our group reviewed the data demonstrating that infusion of modest amounts of ABO incompatible cellular and soluble antigen, and ABO incompatible plasma are associated with clinical harm, including increased mortality.
Tong N, Masel D, Nguyen PL, Asante A, Refaai M, Heal JM, Blumberg N.
The case against infusing ABO incompatible antibody and antigen from all blood components.
Transfus Apher Sci. 2026 Jan 31;65(2):104402. doi: 10.1016/j.transci.2026.104402. Epub ahead of print. PMID: 41633302.
Abstract
The transfusion of ABO compatible but not ABO identical red blood cells and plasma and the transfusion of platelets and cryoprecipitate without concern for ABO in any manner, are practices that have been accepted as safe for patients.
While these practices make managing blood component inventories easier by reducing component outdating, they do lead to the development of immune complexes, donor antibody induced hemolysis, and potentially endothelial cell and platelet injury.
A growing body of evidence has shown that these practices are associated, likely causally, with negative consequences for patients including increased mortality.
The adoption of a policy of providing only ABO identical blood components when practical, and avoiding infusion of ABO incompatible antibody, cellular and soluble antigen should thus become the optimal standard of care for patients.
For those without access to the full article, request a .pdf from [email protected].”
Find more posts featuring Neil Blumberg on Hemostasis Today.
-
Mar 23, 2026, 17:57Prashant Mukkannavar: Making Pain Assessment Accessible and Culturally Relevant for Stroke Survivors
-
Mar 23, 2026, 17:52Avril Mansfield: Does Walking Asymmetry After Stroke Increase the Risk of Lateral Instability and Falls?
-
Mar 23, 2026, 17:47Katherine Caster: Celebrating The Impact and Continued Leadership of AHA In The Fight Against Heart Disease and Stroke
-
Mar 23, 2026, 17:45Archil Jaliashvili: Oxygen’s Journey – 6 Critical Steps to Power the Cell
-
Mar 23, 2026, 17:42Ney Carter Borges: Contemporary Trends and Outcomes of Percutaneous Coronary Intervention for Stent Thrombosis
-
Mar 23, 2026, 17:42Gerrit M. Große: Key Biomarker Research Priorities from BIOSTROKE Collaboration
-
Mar 23, 2026, 17:42Advancing Access to Immunotherapy in Pediatric Oncology in Armenia Through ACT for Children – Yeolyan Hematology and Oncology Center
-
Mar 23, 2026, 17:39Shlomo Sadoun: Systemic Bias in Healthcare Delivery and Outcomes
-
Mar 23, 2026, 17:38Ken Checicki: Expanding Hemophilia Diagnosis in Nigeria Through Mobile Care